Vertex Pharmaceuticals Incorporated (VRTX)
Vertex Pharmaceuticals Incorporated is a Healthcare company in the S&P 500 and the Nasdaq 100, with a market capitalization of about $132.5 billion as of October 1, 2026.
- Ticker
- VRTX · Nasdaq
- Sector
- Healthcare
- Industry (SIC)
- Pharmaceutical Preparations
- Market cap
- $132.5 billion
- Employees
- 6,400
- Headquarters
- Boston, MA
- Fiscal year end
- December 31
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Financial statements
Nvevo shows Vertex Pharmaceuticals Incorporated's income statement, balance sheet, cash flow statement and key ratios as reported in its 10-K and 10-Q filings with the SEC, annually and quarterly, alongside price history, recent news and fair value models.
Other Healthcare companies
- Eli Lilly and Company (LLY)
- Johnson & Johnson (JNJ)
- AbbVie Inc. (ABBV)
- Merck & Co., Inc. (MRK)
- UnitedHealth Group Incorporated (UNH)
- Thermo Fisher Scientific Inc. (TMO)
- Amgen Inc. (AMGN)
- Gilead Sciences, Inc. (GILD)
Research another company · Market map · Stock screener · Compare companies